Return to Sender – Clinical Trial Returns

Article courtesy of ICT (International Clinical Trials) – Oct 2014

Trial planning inevitably focuses on the set-up and timely delivery of studies – and less on later logistics such as the return of unused drugs. But neglecting this issue can lead to scope creep and unexpected costs, which is why early dialogue and decisions on returns are essential.

In recent years, the pharmaceutical industry has witnessed tremendous change in the way it is expected to deliver new drugs to market. This has been driven by several factors.

The industry has faced head-on the prospect of ‘the patent cliff’, losing about $290 billion in revenue from branded prescription medications going off-patent. At the same time,drug development timelines are under constant attack, with speed to market paramount to success. As such, innovation and cost-effi ciency is crucial ….

Read More:

When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?

Your bridge between life-changing therapies and patients